Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactase + lyophilised yoghurt bacteria
- Development stage
- Unknown
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
lactase + lyophilised yoghurt bacteria is a combination product consisting of the enzyme lactase and freeze-dried (lyophilised) bacteria commonly used as yoghurt starter cultures (such as Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus), and sometimes specific probiotic strains like Lactobacillus acidophilus, Bifidobacterium bifidum, or related starter bacteria. This combination is aimed at aiding those with lactose intolerance: lactase enzymatically hydrolyzes lactose into digestible sugars, while lyophilised yoghurt bacteria (which may include probiotics) further facilitate lactose breakdown and help maintain or restore a healthy gut microbiome, potentially improving digestive symptoms in those who have lactose malabsorption. Fermented dairy products with live cultures are better tolerated by lactose-intolerant individuals because both components produce or provide enzymes to break down lactose, and support beneficial colonic microbiota[1][2][3].
02
Targets
GLB1 (Galactosidase Beta 1)
Beyond the preview
Go deeper on lactase + lyophilised yoghurt bacteria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactase + lyophilised yoghurt bacteria.